| 1 |
Zhang ZH, Li LX, Li P, et al. Sirolimus in liver transplant recipients with hepatocellular carcinoma: An updated meta-analysis[J]. J Invest Surg, 2019, 32(7):632-641.
|
| 2 |
Roberts JP. Tumor surveillance-what can and should be done? Screening for recurrence of hepatocellular carcinoma after liver transplantation[J]. Liver Transpl, 2005, 11(suppl 2): S45-S46.
|
| 3 |
Finkenstedt A, Graziadei IW, Oberaigner W, et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients[J]. Am J Transplant, 2009, 9(10):2355-2361.
|
| 4 |
Herrero JI, Pardo F, Dei IW, et al. Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: the effect of smoking withdrawal[J]. Liver Transpl, 2011, 17(4):402-408.
|
| 5 |
Nishihori T, Strazzabosco M, Saif MW. Incidence and management of colorectal cancer in liver transplant recipients[J]. Clin Colorectal Cancer, 2008, 7(4):260-266.
|
| 6 |
Yang PC, Ho CM, Hu RH, et al. Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma[J]. World J Hepatol, 2016, 8(31):1309-1317.
|
| 7 |
Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients[J]. JAMA, 2011, 306(17):1891-1901.
|
| 8 |
KimWR, Terrault NA, Pedersen RA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States[J]. Gastroenterology, 2009, 137(5):1680-1686.
|
| 9 |
Loomba R, Rowley AK, Wesley R, et al. Hepatitis B immunoglobulin and lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis[J]. Clin Gastroenterol Hepatol, 2008, 6(6):696-700.
|
| 10 |
Rao W, Wu X, Xiu D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis[J]. Transpl Int, 2009, 22(4):387-394.
|
| 11 |
Katz LH, Paul M, Guy DG, et al. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis[J]. Transpl Infect Dis, 2010, 12(4):292-308.
|
| 12 |
Dan YY, Wai CT, Yeoh KG, et al. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a costeffectiveness analysis[J]. Liver Transpl, 2006, 12(5):736-746.
|
| 13 |
Fox AN, Terrault NA. The option of HBIG-free prophylaxis against recurrent HBV[J]. J Hepatol, 2012, 56(5):1189-1197.
|
| 14 |
Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Liver Transpl, 2013, 19(1):3-26.
|
| 15 |
Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients[J]. Liver Transpl, 2006, 12(8):1192-1204.
|
| 16 |
Kalambokis G, Manousou P, Samonakis D, et al. Clinical outcome of HCV related graft cirrhosis and prognostic value of hepatic venous pressure gradient[J]. Transpl Int, 2009, 22(2): 172-181.
|
| 17 |
Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation[J]. Gastroenterology, 2002, 122(4):889-896.
|
| 18 |
Neumann UP, Berg T, Bahra M, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up[J]. Transplantation, 2004, 77(2):226-231.
|
| 19 |
Lake JR, Shorr JS, Steffen BJ, et al. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis[J]. Am J Transplant, 2005, 5(3):549-557.
|
| 20 |
Wiesner RH, Sorrell M, Villamil F; International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C[J]. Liver Transpl, 2003, 9(11):S1-S9.
|
| 21 |
Veldt BJ, Poterucha JJ, Watt KD, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection[J]. Am J Transplant, 2008, 8(11):2426-2433.
|
| 22 |
Xirouchakis E, Triantos C, Manousou P, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies[J]. J Viral Hepat, 2008, 15(10):699-709.
|
| 23 |
European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection[J]. J Hepatol, 2014, 60(2):392-420.
|
| 24 |
Shaffer AA, Thomas AG, Bowring MG, et al. Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey[J]. Transpl Infect Dis, 2018, 20(6): e12982.
|
| 25 |
Bernuth S, Grimm D, Vollmar J, et al. Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort[J]. Drug Des Devel Therm, 2017, 11:2131-2138.
|
| 26 |
Rupp C, Hippchen T, Neuberger M, et al. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus[J]. World J Gastroenterol, 2018, 24(12):1353-1360.
|
| 27 |
A special meeting review edition: Advances in the treatment of hepatitis C virus infection from EASL 2015: The 50th annual meeting of the European Association for the Study of the Liver[J]. Gastroenterol Hepatol (N Y), 2015, 11(6 Suppl 3):1-23.
|
| 28 |
中华医学会肝病学分会，中华医学会感染病学分会. 丙型肝炎防治指南(2015更新版)[J]. 中华肝脏病杂志，2015, 23(12):906-923.
|
| 29 |
Burgess S, Partovi N, Yoshida EM, et al. Drug interactions with direct-acting antivirals for hepatitis C: Implications for HIV and transplant patients[J]. Ann Pharmacother, 2015, 49(6):674-687.
|
| 30 |
Neuberger J. Recurrent primary biliary cirrhosis[J]. Liver Transpl, 2003, 9(6):539-546.
|
| 31 |
Hubscher SG, Elias E, Buckels JA, et al. Primary biliary cirrhosis. Histological evidence of disease recurrence after liver transplantation[J]. J Hepatol, 1993, 18(2):173-184.
|
| 32 |
Neuberger J, Gunson B, Hubscher S, et al. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation[J]. Liver Transpl, 2004, 10(4):488-491.
|
| 33 |
Fosby B, Karlsen TH, Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis[J]. World J Gastroenterol, 2012, 18(1):1-15.
|
| 34 |
Joshi D, Bjarnason I, Belgaumkar A, et al. The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis[J]. Liver Int, 2013, 33(1):53-61.
|
| 35 |
Tripathi D, Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease[J]. Semin Liver Dis, 2009, 29(3):286-296.
|
| 36 |
Lucey MR. Liver transplantation in patients with alcoholic liver disease[J]. Liver Transpl, 2011, 17:751-759.
|
| 37 |
Kodali S, Kaif M, Tariq R, et al. Alcohol relapse after liver transplantation for alcoholic cirrhosis-impact on liver graft and patient survival: A meta-analysis[J]. Alcohol Alcohol, 2018, 53(2):166-172.
|
| 38 |
Deutsch-Link S, Weinrieb RM, Jones LS, et al. Prior relapse, ongoing alcohol consumption, and failure to engage in treatment predict alcohol relapse after liver transplantation[J]. Dig Dis Sci, 2019. [Epub ahead of print]
|
| 39 |
Watt KD, Pedersen RA, Kremers WK, et al. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study[J]. Am J Transplant, 2010, 10(6):1420-1427.
|
| 40 |
Golabi P, Bush H, Stepanova M, et al. Liver transplantation (LT) for cryptogenic cirrhosis (CC) and nonalcoholic steatohepatitis (NASH) cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016[J]. Medicine (Baltimore), 2018, 97(31): e11518.
|
| 41 |
Byrne CD, Targher G. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate？[J]. Diabetologia, 2016, 59(6):1141-1144.
|
| 42 |
Oyrne CD, Targher G. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fattythan those with hepatitis C to receive liver transplants[J]. Clin Gastroenterol Hepatol, 2011, 9(8):700-704: e1.
|
| 43 |
Aller R, Fernández-Rodríguez C, Lo Iacono O, et al. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical Practice Guideline[J]. Gastroenterol Hepatol, 2018, 41(5):328-349. [Article in English, Spanish]
|
| 44 |
Bzowej NH. Nonalcoholic steatohepatitis: the new frontier for liver transplantation[J]. Curr Opin Organ Transplant, 2018, 23(2):169-174.
|
| 45 |
Kappus M, Abdelmalek M. De novo and recurrence of nonalcoholic steatohepatitis after liver transplantation[J]. Clin Liver Dis, 2017, 21(2):321-335.
|
| 46 |
Yalamanchili K, Saadeh S, Klintmalm GB, et al. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease[J]. Liver Transpl, 2010, 16(4):431-439.
|
| 47 |
Andrade ARCF, Cotrim HP, Bittencourt PL, et al. Nonalcoholic steatohepatitis in post-transplantation liver: Review article[J]. Rev Assoc Med Bras(1992), 2018, 64(2):187-194.
|